Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer

E J Campbell; E McDuff; O Tatarov; S Tovey; V Brunton; T G Cooke; J Edwards

doi:10.1038/sj.bjc.6604768

Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer

E J Campbell, E McDuff, O Tatarov, S Tovey, V Brunton, T G Cooke, J Edwards

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Elevated c-Src protein expression has been shown in breast cancer and in vitro evidence suggests a role in endocrine resistance. To investigate whether c-Src is involved in endocrine resistance, we examined the expression of both total and activated c-Src in human breast cancer specimens from a cohort of oestrogen receptor (ER)-positive tamoxifen-treated breast cancer patients. Tissue microarray technology was employed to analyse 262 tumour specimens taken before tamoxifen treatment. Immunohistochemistry using total c-Src and activated c-Src antibodies was performed. Kaplan-Meier survival curves were constructed and log-rank test were performed. High level of nuclear activated Src was significantly associated with improved overall survival (P=0.047) and lower recurrence rates on tamoxifen (P=0.02). Improved patient outcome was only seen with activated Src in the nucleus. Nuclear activated Src expression was significantly associated with node-negative disease and a lower NPI (P

Original language	English
Pages (from-to)	1769-74
Number of pages	6
Journal	British Journal of Cancer
Volume	99
Issue number	11
DOIs	https://doi.org/10.1038/sj.bjc.6604768
Publication status	Published - 2008

Access to Document

10.1038/sj.bjc.6604768

Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer
BJC open article
Final published version, 210 KB

http://www.nature.com/bjc/journal/v99/n11/full/6604768a.html

Cite this

@article{0dcb65c7d66b4143ad371b3c999cb186,

title = "Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer",

abstract = "Elevated c-Src protein expression has been shown in breast cancer and in vitro evidence suggests a role in endocrine resistance. To investigate whether c-Src is involved in endocrine resistance, we examined the expression of both total and activated c-Src in human breast cancer specimens from a cohort of oestrogen receptor (ER)-positive tamoxifen-treated breast cancer patients. Tissue microarray technology was employed to analyse 262 tumour specimens taken before tamoxifen treatment. Immunohistochemistry using total c-Src and activated c-Src antibodies was performed. Kaplan-Meier survival curves were constructed and log-rank test were performed. High level of nuclear activated Src was significantly associated with improved overall survival (P=0.047) and lower recurrence rates on tamoxifen (P=0.02). Improved patient outcome was only seen with activated Src in the nucleus. Nuclear activated Src expression was significantly associated with node-negative disease and a lower NPI (P",

author = "Campbell, {E J} and E McDuff and O Tatarov and S Tovey and V Brunton and Cooke, {T G} and J Edwards",

year = "2008",

doi = "10.1038/sj.bjc.6604768",

language = "English",

volume = "99",

pages = "1769--74",

journal = "British Journal of Cancer",

issn = "1532-1827",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer

AU - Campbell, E J

AU - McDuff, E

AU - Tatarov, O

AU - Tovey, S

AU - Brunton, V

AU - Cooke, T G

AU - Edwards, J

PY - 2008

Y1 - 2008

N2 - Elevated c-Src protein expression has been shown in breast cancer and in vitro evidence suggests a role in endocrine resistance. To investigate whether c-Src is involved in endocrine resistance, we examined the expression of both total and activated c-Src in human breast cancer specimens from a cohort of oestrogen receptor (ER)-positive tamoxifen-treated breast cancer patients. Tissue microarray technology was employed to analyse 262 tumour specimens taken before tamoxifen treatment. Immunohistochemistry using total c-Src and activated c-Src antibodies was performed. Kaplan-Meier survival curves were constructed and log-rank test were performed. High level of nuclear activated Src was significantly associated with improved overall survival (P=0.047) and lower recurrence rates on tamoxifen (P=0.02). Improved patient outcome was only seen with activated Src in the nucleus. Nuclear activated Src expression was significantly associated with node-negative disease and a lower NPI (P

AB - Elevated c-Src protein expression has been shown in breast cancer and in vitro evidence suggests a role in endocrine resistance. To investigate whether c-Src is involved in endocrine resistance, we examined the expression of both total and activated c-Src in human breast cancer specimens from a cohort of oestrogen receptor (ER)-positive tamoxifen-treated breast cancer patients. Tissue microarray technology was employed to analyse 262 tumour specimens taken before tamoxifen treatment. Immunohistochemistry using total c-Src and activated c-Src antibodies was performed. Kaplan-Meier survival curves were constructed and log-rank test were performed. High level of nuclear activated Src was significantly associated with improved overall survival (P=0.047) and lower recurrence rates on tamoxifen (P=0.02). Improved patient outcome was only seen with activated Src in the nucleus. Nuclear activated Src expression was significantly associated with node-negative disease and a lower NPI (P

U2 - 10.1038/sj.bjc.6604768

DO - 10.1038/sj.bjc.6604768

M3 - Article

C2 - 19018258

SN - 1532-1827

VL - 99

SP - 1769

EP - 1774

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 11

ER -

Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer

Abstract / Description of output

Access to Document

Fingerprint

Cite this